 NEW YORK, Nov. 05, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells UCART, today announced its results for the three-month and nine-month periods ending September 30, 2020. 